EGFR and melanoma: Nevertheless, in a large scale study of 150 small molecule inhibitors in a panel of 28 early passage melanoma lines[39] analysis showed that the most effective drug combination for BRAF-mutant lines was that of vemurafenib, EGFR, and AKT inhibitors, which was cytotoxic even in lines with primary resistance to vemurafenib or in lines selected for resistance to vemurafenib.